Science Market Update

University of Utah Virtual BioResearch Product Faire™ Event Oct 14, 2020

Posted by BCI Staff on Mon, Oct 12, 2020

University of Utah

BioResearch Product Faire™


Virtual Event: Wednesday, October 14, 2020

Attendance is free for science professionals.

Read More

Tags: UUtah, University of Utah Salt Lake City, 2020

Utah’s Department of Bioengineering Spends $17M Annually on Research and Produces Breakthrough in 3D Bioprinting

Posted by Rebecca Inch-Partridge on Fri, Dec 28, 2018

The University of Utah is recognized as a Top-Tier 1 research university by the Carnegie Classification of Institutions in Higher Education. According to the Vice President of Research the University was awarded 2,326 grants in 2018 and had $515 million in research funding. According to the National Institutes of Health, the university received $152,843,112 from them this year.

Read More

Tags: Utah, University of Utah Salt Lake City, Univ of Utah, BioResearch Product Faire™, 3D Printing and Medical Devices, university research funding, 3D bioprinting

NIH awards $11.5 Million Grant to The University of Utah

Posted by Andrea Inks on Tue, Dec 11, 2018

The NIH awarded $11.5 million grant to The University of Utah to Study Sarcomagenesis.

Read More

Tags: Utah, cancer research, University of Utah Salt Lake City, Univ of Utah, sarcomagenesis, Jones Lab

Scientists Address Gender Biases in Life Science Research at U. Utah

Posted by Jennifer Nieuwkerk on Fri, Sep 26, 2014

The National Institutes of Health have recently been making a push for life science researchers across the country to address gender biases in their studies. In conjunction with these efforts, the NIH announced this September that it will give out $10.1 million in grants to more than 80 scientists studying a range of subjects, as long as the researchers agree to include females in their studies.

Read More

Tags: migraine research, University of Utah Salt Lake City

Life Science Researchers at U. Utah Discover Leukemia Gene Mutation

Posted by Jennifer Nieuwkerk on Tue, Sep 23, 2014

Leukemia is a cancer that’s unusual in that it begins in the bone marrow and invades the blood. The most prominent treatment options – drugs called tyrosine kinase inhibitors – have allowed for a 95 percent survival rate over the past five years and also allow leukemia patients to lead relatively normal lives.

"Fortunately, the problems we are studying affect a minority of chronic myeloid leukemia patients, but still, this leaves some patients with no good treatment option at all," said lead author and University of Utah life science researcher Dr. Thomas O'Hare. "Our goal is to have a tyrosine kinase inhibitor option for every patient."

Read More

Tags: 2014, Utah, UUtah, cancer research, UT, University of Utah Salt Lake City

Subscribe to Company News